OptimizeRx Corporation reported its financial results for the third quarter ended September 30, 2026, and updated its fiscal year 2026 guidance. The company reported a decrease in revenue for the quarter, but an increase in profitability metrics and a reduction in outstanding debt.
For the three months ended September 30, 2026, OptimizeRx generated total revenue of $21.6 million. This figure represents a 17% decrease compared to the $26.1 million reported in the same period of the prior year. Despite the revenue decline, the company reported GAAP net income of $1.2 million, or $0.06 per basic and diluted share, compared to $0.8 million, or $0.04 per share, in Q3 2025.
On a non-GAAP basis, the company reported net income of $3.8 million, or $0.20 per diluted share, for Q3 2026, up from $3.1 million, or $0.16 per diluted share, in the prior year. Adjusted EBITDA for the quarter was $6.3 million, an increase from $5.1 million in Q3 2025. The company noted that adjusted EBITDA margins expanded by over 900 basis points year-over-year.
OptimizeRx also provided updated guidance for fiscal year 2026. The company now expects full-year revenue to be between $87 million and $93 million. Adjusted EBITDA guidance for the year remains unchanged, with the company expecting a range of $21 million to $25 million.
In terms of balance sheet position, the company reported cash and cash equivalents of $22.3 million as of September 30, 2026, a slight decrease from $23.4 million at the end of 2025. The company also noted that it repaid $9.3 million in debt principal since June 30, 2026, reducing its current outstanding principal to $10.4 million.
Key performance indicators for the rolling 12 months ended September 30, 2026, showed that the average revenue per top 20 pharmaceutical manufacturer was $2,504, down from $3,087 in the prior year. The percent of total revenue attributable to the top 20 manufacturers was 53%, compared to 56% in the prior year. Net revenue retention was reported at 83%, and revenue per average full-time employee was $706, compared to $820 in the prior year.
